Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Aclaris Therapeutics Inc ACRS

Healthcare
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on... see more

Recent & Breaking News (NDAQ:ACRS)

Aclaris Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

GlobeNewswire June 6, 2024

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

GlobeNewswire May 7, 2024

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

GlobeNewswire April 30, 2024

Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

PR Newswire April 23, 2024

Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update

GlobeNewswire February 27, 2024

Aclaris Therapeutics Announces Leadership Changes and Strategic Business Review

GlobeNewswire January 16, 2024

Aclaris Therapeutics Announces Top-line Results from 4-Week Phase 2b Trial of ATI-1777 for Mild to Severe Atopic Dermatitis

GlobeNewswire January 10, 2024

Aclaris Therapeutics Provides Corporate Update

GlobeNewswire December 19, 2023

Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia

GlobeNewswire December 5, 2023

Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update

GlobeNewswire November 13, 2023

Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update

GlobeNewswire November 6, 2023

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of ATI-1777 for Mild to Severe Atopic Dermatitis (ATI-1777-AD-202)

GlobeNewswire October 3, 2023

Aclaris Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

GlobeNewswire September 20, 2023

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

GlobeNewswire September 18, 2023

Aclaris Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Corporate Update

GlobeNewswire August 7, 2023

Aclaris Therapeutics Completes Enrollment in Phase 2b Study of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis (ATI-450-RA-202)

GlobeNewswire June 13, 2023

Aclaris Therapeutics to Participate in Two June Healthcare Investor Conferences

GlobeNewswire June 2, 2023

Aclaris Therapeutics Reports First Quarter 2023 Financial Results and Provides a Corporate Update

GlobeNewswire May 8, 2023

Aclaris Therapeutics to Announce First Quarter 2023 Financial Results on May 8, 2023

GlobeNewswire May 2, 2023

Aclaris Therapeutics to Participate in the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference

GlobeNewswire March 27, 2023